Impact of the Alzheimer's Disease Neuroimaging Initiative, 2004 to 2014

Michael W. Weiner; Dallas P. Veitch; Paul S. Aisen; Laurel A. Beckett; Nigel J. Cairns; Jesse Cedarbaum; Michael C. Donohue; Robert C. Green; Danielle Harvey; Clifford R. Jack; William Jagust; John C. Morris; Ronald C. Petersen; Andrew J. Saykin; Leslie Shaw; Paul M. Thompson; Arthur W. Toga; John Q. Trojanowski

doi:10.1016/j.jalz.2015.04.005

Impact of the Alzheimer's Disease Neuroimaging Initiative, 2004 to 2014

Michael W. Weiner, Dallas P. Veitch, Paul S. Aisen, Laurel A. Beckett, Nigel J. Cairns, Jesse Cedarbaum, Michael C. Donohue, Robert C. Green, Danielle Harvey, Clifford R. Jack, William Jagust, John C. Morris, Ronald C. Petersen, Andrew J. Saykin, Leslie Shaw, Paul M. Thompson, Arthur W. Toga, John Q. Trojanowski

Research output: Contribution to journal › Review article › peer-review

101 Scopus citations

Abstract

Introduction The Alzheimer's Disease Neuroimaging Initiative (ADNI) was established in 2004 to facilitate the development of effective treatments for Alzheimer's disease (AD) by validating biomarkers for AD clinical trials. Methods We searched for ADNI publications using established methods. Results ADNI has (1) developed standardized biomarkers for use in clinical trial subject selection and as surrogate outcome measures; (2) standardized protocols for use across multiple centers; (3) initiated worldwide ADNI; (4) inspired initiatives investigating traumatic brain injury and post-traumatic stress disorder in military populations, and depression, respectively, as an AD risk factor; (5) acted as a data-sharing model; (6) generated data used in over 600 publications, leading to the identification of novel AD risk alleles, and an understanding of the relationship between biomarkers and AD progression; and (7) inspired other public-private partnerships developing biomarkers for Parkinson's disease and multiple sclerosis. Discussion ADNI has made myriad impacts in its first decade. A competitive renewal of the project in 2015 would see the use of newly developed tau imaging ligands, and the continued development of recruitment strategies and outcome measures for clinical trials.

Original language	English (US)
Pages (from-to)	865-884
Number of pages	20
Journal	Alzheimer's and Dementia
Volume	11
Issue number	7
DOIs	https://doi.org/10.1016/j.jalz.2015.04.005
State	Published - Jul 1 2015

Keywords

AD biomarker signature
Alzheimer's disease
Amyloid phenotyping
Clinical trial biomarkers
Data-sharing
Tau imaging
Worldwide ADNI

ASJC Scopus subject areas

Epidemiology
Health Policy
Developmental Neuroscience
Clinical Neurology
Geriatrics and Gerontology
Psychiatry and Mental health
Cellular and Molecular Neuroscience

Access to Document

10.1016/j.jalz.2015.04.005

Fingerprint Dive into the research topics of 'Impact of the Alzheimer's Disease Neuroimaging Initiative, 2004 to 2014'. Together they form a unique fingerprint.

Cite this

Weiner, M. W., Veitch, D. P., Aisen, P. S., Beckett, L. A., Cairns, N. J., Cedarbaum, J., Donohue, M. C., Green, R. C., Harvey, D., Jack, C. R., Jagust, W., Morris, J. C., Petersen, R. C., Saykin, A. J., Shaw, L., Thompson, P. M., Toga, A. W., & Trojanowski, J. Q. (2015). Impact of the Alzheimer's Disease Neuroimaging Initiative, 2004 to 2014. Alzheimer's and Dementia, 11(7), 865-884. https://doi.org/10.1016/j.jalz.2015.04.005

Impact of the Alzheimer's Disease Neuroimaging Initiative, 2004 to 2014. / Weiner, Michael W.; Veitch, Dallas P.; Aisen, Paul S.; Beckett, Laurel A.; Cairns, Nigel J.; Cedarbaum, Jesse; Donohue, Michael C.; Green, Robert C.; Harvey, Danielle; Jack, Clifford R.; Jagust, William; Morris, John C.; Petersen, Ronald C.; Saykin, Andrew J.; Shaw, Leslie; Thompson, Paul M.; Toga, Arthur W.; Trojanowski, John Q.

In: Alzheimer's and Dementia, Vol. 11, No. 7, 01.07.2015, p. 865-884.

Research output: Contribution to journal › Review article › peer-review

Weiner, MW, Veitch, DP, Aisen, PS, Beckett, LA, Cairns, NJ, Cedarbaum, J, Donohue, MC, Green, RC, Harvey, D, Jack, CR, Jagust, W, Morris, JC, Petersen, RC, Saykin, AJ, Shaw, L, Thompson, PM, Toga, AW & Trojanowski, JQ 2015, 'Impact of the Alzheimer's Disease Neuroimaging Initiative, 2004 to 2014', Alzheimer's and Dementia, vol. 11, no. 7, pp. 865-884. https://doi.org/10.1016/j.jalz.2015.04.005

Weiner, Michael W. ; Veitch, Dallas P. ; Aisen, Paul S. ; Beckett, Laurel A. ; Cairns, Nigel J. ; Cedarbaum, Jesse ; Donohue, Michael C. ; Green, Robert C. ; Harvey, Danielle ; Jack, Clifford R. ; Jagust, William ; Morris, John C. ; Petersen, Ronald C. ; Saykin, Andrew J. ; Shaw, Leslie ; Thompson, Paul M. ; Toga, Arthur W. ; Trojanowski, John Q. / Impact of the Alzheimer's Disease Neuroimaging Initiative, 2004 to 2014. In: Alzheimer's and Dementia. 2015 ; Vol. 11, No. 7. pp. 865-884.

@article{2f880f533e7544a5ad8ba74673fa6f4f,

title = "Impact of the Alzheimer's Disease Neuroimaging Initiative, 2004 to 2014",

abstract = "Introduction The Alzheimer's Disease Neuroimaging Initiative (ADNI) was established in 2004 to facilitate the development of effective treatments for Alzheimer's disease (AD) by validating biomarkers for AD clinical trials. Methods We searched for ADNI publications using established methods. Results ADNI has (1) developed standardized biomarkers for use in clinical trial subject selection and as surrogate outcome measures; (2) standardized protocols for use across multiple centers; (3) initiated worldwide ADNI; (4) inspired initiatives investigating traumatic brain injury and post-traumatic stress disorder in military populations, and depression, respectively, as an AD risk factor; (5) acted as a data-sharing model; (6) generated data used in over 600 publications, leading to the identification of novel AD risk alleles, and an understanding of the relationship between biomarkers and AD progression; and (7) inspired other public-private partnerships developing biomarkers for Parkinson's disease and multiple sclerosis. Discussion ADNI has made myriad impacts in its first decade. A competitive renewal of the project in 2015 would see the use of newly developed tau imaging ligands, and the continued development of recruitment strategies and outcome measures for clinical trials.",

keywords = "AD biomarker signature, Alzheimer's disease, Amyloid phenotyping, Clinical trial biomarkers, Data-sharing, Tau imaging, Worldwide ADNI",

author = "Weiner, {Michael W.} and Veitch, {Dallas P.} and Aisen, {Paul S.} and Beckett, {Laurel A.} and Cairns, {Nigel J.} and Jesse Cedarbaum and Donohue, {Michael C.} and Green, {Robert C.} and Danielle Harvey and Jack, {Clifford R.} and William Jagust and Morris, {John C.} and Petersen, {Ronald C.} and Saykin, {Andrew J.} and Leslie Shaw and Thompson, {Paul M.} and Toga, {Arthur W.} and Trojanowski, {John Q.}",

year = "2015",

month = jul,

day = "1",

doi = "10.1016/j.jalz.2015.04.005",

language = "English (US)",

volume = "11",

pages = "865--884",

journal = "Alzheimer's and Dementia",

issn = "1552-5260",

publisher = "Elsevier Inc.",

number = "7",

}

TY - JOUR

T1 - Impact of the Alzheimer's Disease Neuroimaging Initiative, 2004 to 2014

AU - Weiner, Michael W.

AU - Veitch, Dallas P.

AU - Aisen, Paul S.

AU - Beckett, Laurel A.

AU - Cairns, Nigel J.

AU - Cedarbaum, Jesse

AU - Donohue, Michael C.

AU - Green, Robert C.

AU - Harvey, Danielle

AU - Jack, Clifford R.

AU - Jagust, William

AU - Morris, John C.

AU - Petersen, Ronald C.

AU - Saykin, Andrew J.

AU - Shaw, Leslie

AU - Thompson, Paul M.

AU - Toga, Arthur W.

AU - Trojanowski, John Q.

PY - 2015/7/1

Y1 - 2015/7/1

N2 - Introduction The Alzheimer's Disease Neuroimaging Initiative (ADNI) was established in 2004 to facilitate the development of effective treatments for Alzheimer's disease (AD) by validating biomarkers for AD clinical trials. Methods We searched for ADNI publications using established methods. Results ADNI has (1) developed standardized biomarkers for use in clinical trial subject selection and as surrogate outcome measures; (2) standardized protocols for use across multiple centers; (3) initiated worldwide ADNI; (4) inspired initiatives investigating traumatic brain injury and post-traumatic stress disorder in military populations, and depression, respectively, as an AD risk factor; (5) acted as a data-sharing model; (6) generated data used in over 600 publications, leading to the identification of novel AD risk alleles, and an understanding of the relationship between biomarkers and AD progression; and (7) inspired other public-private partnerships developing biomarkers for Parkinson's disease and multiple sclerosis. Discussion ADNI has made myriad impacts in its first decade. A competitive renewal of the project in 2015 would see the use of newly developed tau imaging ligands, and the continued development of recruitment strategies and outcome measures for clinical trials.

AB - Introduction The Alzheimer's Disease Neuroimaging Initiative (ADNI) was established in 2004 to facilitate the development of effective treatments for Alzheimer's disease (AD) by validating biomarkers for AD clinical trials. Methods We searched for ADNI publications using established methods. Results ADNI has (1) developed standardized biomarkers for use in clinical trial subject selection and as surrogate outcome measures; (2) standardized protocols for use across multiple centers; (3) initiated worldwide ADNI; (4) inspired initiatives investigating traumatic brain injury and post-traumatic stress disorder in military populations, and depression, respectively, as an AD risk factor; (5) acted as a data-sharing model; (6) generated data used in over 600 publications, leading to the identification of novel AD risk alleles, and an understanding of the relationship between biomarkers and AD progression; and (7) inspired other public-private partnerships developing biomarkers for Parkinson's disease and multiple sclerosis. Discussion ADNI has made myriad impacts in its first decade. A competitive renewal of the project in 2015 would see the use of newly developed tau imaging ligands, and the continued development of recruitment strategies and outcome measures for clinical trials.

KW - AD biomarker signature

KW - Alzheimer's disease

KW - Amyloid phenotyping

KW - Clinical trial biomarkers

KW - Data-sharing

KW - Tau imaging

KW - Worldwide ADNI

UR - http://www.scopus.com/inward/record.url?scp=84937573808&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84937573808&partnerID=8YFLogxK

U2 - 10.1016/j.jalz.2015.04.005

DO - 10.1016/j.jalz.2015.04.005

M3 - Review article

C2 - 26194320

AN - SCOPUS:84937573808

VL - 11

SP - 865

EP - 884

JO - Alzheimer's and Dementia

JF - Alzheimer's and Dementia

SN - 1552-5260

IS - 7

ER -